Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Registry to Measure the Impact of Adding Genomic Testing (Prolaris®) on the Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients by Specialists

NCT02209584 is registered in ClinicalTrials.gov with Myriad Genetic Laboratories, Inc. as lead sponsor.

NCT NCT02209584
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02209584 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Registry to Measure the Impact of Adding Genomic Testing (Prolaris®) on the Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients by Specialists
Lead sponsor
Myriad Genetic Laboratories, Inc.
Phase
Observational
Overall status
Completed
Start date
May 31, 2014
Completion date
December 8, 2015
Enrollment
274 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer